Syntrix Biosystems, Inc.
Clinical trials sponsored by Syntrix Biosystems, Inc., explained in plain language.
-
New drug combo takes on Hard-to-Treat bone marrow cancer
Disease control Recruiting nowThis early-stage trial is testing a new oral drug called SX-682, alone or with the chemotherapy drug decitabine, in people with myelodysplastic syndrome (MDS) — a bone marrow disorder. The main goal is to find a safe dose and check for side effects. About 151 adults whose MDS has…
Phase: PHASE1 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Jun 23, 2026 23:34 UTC
-
New combo therapy aims to fight hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests a new drug combination (SX-682 plus enzalutamide) in 53 men with metastatic castration-resistant prostate cancer that has worsened despite prior treatments. The goal is to see if the combination can shrink tumors, lower PSA levels, or keep the cancer stable for a…
Phase: PHASE2 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC